Clinical-stage biotechnology company developing first-in-class precision therapies for inflammatory, immunological, and rare diseases
Clinical-stage biotechnology company developing first-in-class precision therapies for inflammatory, immunological, and rare diseases. Its GRID AI platform integrates curated biomedical data and machine-learning models across drug discovery and clinical development. The pipeline includes kinase-modulating small-molecule therapies, including a Phase 2 program for ARDS and programs for rare diseases such as Duchenne muscular dystrophy.